Monograph Details
|
|
Neoplasms
> Hormones and antagonists
|
|
FASLODEX |
| Manufacturer |
|
AstraZeneca Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Estrogen receptor antagonist. |
| Generic Name |
|
Fulvestrant 50mg/mL; soln for IM inj. |
| Indications |
|
Hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. |
| Children |
|
Not applicable. |
| Adults |
|
Give by IM inj into buttocks. 250mg once per month. May give as one 5mL injection or as two 2.5mL injections given concurrently. |
| Contraindications |
|
Pregnancy (Cat.D); exclude pregnancy before starting. |
| Precautions |
|
Moderate to severe hepatic impairment. Nursing mothers: not recommended. |
| Adverse Reactions |
|
GI disturbances, asthenia, pain (eg, back, pelvic, headache, inj site), hot flushes, pharyngitis, dyspnea. |
| How Supplied |
Prefilled syringe (2 x 2.5mL)—1
Prefilled syringe (1 x 5mL)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
